Still Needled By Icahn, Forest Nominates Three To Board

The specialty pharma countered the activist investor's June challenge with its own nominees, while defending its diversification strategy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet